Company / Return on Equity (ROE)
Nurix Therapeutics, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-49.1%
FY2025
5-year range
-71.8% / -7.5%
FY2021-FY2025
Trend
-33.7%
vs FY2024
Sector context
#132 of 190
Health Care
What the data says
Nurix Therapeutics, Inc. reports negative total equity of -49.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-49.1% in FY2025 with a 5-year CAGR of -34.2%.
Improved from -71.8% to -49.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -14.9pp
- 5-Year Change
- -34.2pp
- 10-Year Change
- -
Sector benchmark
#132 of 190 in Health CareTop 69% of 190This company -49.1% Sector average -50.4%
▼
+2.7% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 33.7% year-over-year.
- Currently 1.3pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -49.1% | -33.7% |
| FY2024 | -36.7% | +48.8% |
| FY2023 | -71.8% | -109.7% |
| FY2022 | -34.2% | -357.8% |
| FY2021 | -7.5% | +49.8% |
| FY2020 | -14.9% | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026